Integrins as therapeutic targets: lessons and opportunities

被引：372

作者：

Cox, Dermot ^{[1
]}

Brennan, Marian ^{[1
]}

Moran, Niamh ^{[1
]}

机构：

[1] Royal Coll Surgeons Ireland, Dublin 2, Ireland

来源：

NATURE REVIEWS DRUG DISCOVERY | 2010年 / 9卷 / 10期

关键词：

PLATELET GLYCOPROTEIN IIB/IIIA; FUNCTION-ASSOCIATED ANTIGEN-1; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ACUTE CORONARY SYNDROMES; SMALL-MOLECULE ANTAGONIST; PLACEBO-CONTROLLED TRIAL; SEVERE PLAQUE PSORIASIS; I-LIKE DOMAIN; ARG-GLY-ASP; INTERCELLULAR-ADHESION MOLECULE-1;

D O I：

10.1038/nrd3266

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The integrins are a large family of cell adhesion molecules that are essential for the regulation of cell growth and function. The identification of key roles for integrins in a diverse range of diseases, including cancer, infection, thrombosis and autoimmune disorders, has revealed their substantial potential as therapeutic targets. However, so far, pharmacological inhibitors for only three integrins have received marketing approval. This article discusses the structure and function of integrins, their roles in disease and the chequered history of the approved integrin antagonists. Recent advances in the understanding of integrin function, ligand interaction and signalling pathways suggest novel strategies for inhibiting integrin function that could help harness their full potential as therapeutic targets.

引用

页码：804 / 820

页数：17

共 205 条

[1] Antithrombotic effects of targeting αIIbβ3 signaling in platelets [J].